% | $
Quotes you view appear here for quick access.

Pharmacyclics, Inc. Message Board

  • freshwaterfish57 freshwaterfish57 Dec 2, 2012 10:07 AM Flag

    Insight to the already know public info

    Before ibrutinib gets any sales, it must get regulatory approval, which isn't seen until 2015 because the company has to complete a late-stage trial, analysts say. In a larger trial, the potential exists for unforeseen complications or weaker efficacy readings,

    Other companies are pursuing drugs that target the same enzyme, including developmental CLL drugs at Celgene Corp. (CELG), and Gilead Sciences Inc. (GILD), which seems to be moving faster with the studies of its GS-1101, CAL 101 and other, The market may not be big enough, soon enough, to support the revenue implied by the PCYC stock's recent valuation. This is exciting though so stay tuned. GA101, TRU016, CAL101, University of Pennsylvania research, John Kanzius Foundation. Also watch further development with the Nanobody King... ABLYNX in Netherlands ABLX.BR ...... US ADR is ABLYF, and XMAB from Xencor in California. It has several serious partnerships to beat PCYC to the finish line. GLTA

257.100.00(0.00%)Apr 23 3:59 PMEDT